Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT CLAIMING THE CHAMPIONSHIP OF THE 2026 XIONGAN INTERNATIONAL MEDICAL AND HEALTH TECHNOLOGY APPLICATION COMPETITION AND RECENT RELEASE OF MAJOR SCIENTIFIC RESEARCH ACHIEVEMENTS

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司(the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the Group has recently achieved important breakthroughs in various areas, the details of which are announced as follows:

I. CLAIMING THE CHAMPIONSHIP OF THE 2026 XIONGAN INTERNATIONAL MEDICAL AND HEALTH TECHNOLOGY APPLICATION COMPETITION

The finals of the 2026 Xiongan International Medical and Health Technology Application Competition were recently held in Xiongan New Area. Hosted by the Xiongan Future City Scenario Collection Organizing Committee, the competition was themed "Digital Intelligence Healthcare Empowers Future Health" (數智醫療健康未來) and covered three application scenarios: health big data application technology, new smart hospital scenarios, and the inheritance and innovative development of traditional Chinese medicine. The competition attracted 666 projects from 514 domestic and international business entities, with 173 projects advancing to the finals after several rounds of selection.

By submitting the project "Application of Digital Diagnosis and Treatment Platform for Cognitive Impairment Based on Large Models in the Medical Field", the Group competed in the new smart hospital application scenarios against 40 teams including Tsinghua University, Peking University, Beijing Tongren Hospital affiliated with the Capital Medical University, and Hebei Medical University, and finally claimed the first place and was awarded the championship title.

This award is of significance to the Group, as the competition is supported by national industry societies (Chinese Medical Association, Chinese Preventive Medicine Association, China Association of Medical Equipment, China Information Association for Traditional Chinese Medicine and Pharmacy, etc.) as a nationally influential event in the medical and health field. The Group's emergence from numerous projects to win the championship fully demonstrates its technological leadership and industry recognition in the fields of digital medicine and AI medicine.

II. RECENT RELEASE OF MAJOR SCIENTIFIC RESEARCH ACHIEVEMENTS

In the first half of 2026, the Group achieved a series of important scientific research results in the cross-disciplinary field of brain science and AI medicine, with a number of studies published in top international academic journals:

(1) 7T Ultra-high-field MRI Reveals Brain Mechanisms of Hypertension Damage ("Brain Research")

On June 23, 2026, the research results, with extensive participation and support from the research team led by Professor Ma Changsheng from Beijing Anzhen Hospital affiliated with Capital Medical University, the team led by Professor Wang Jiguang from Ruijin Hospital affiliated with School of Medicine, Shanghai Jiao Tong University, and the Group's scientific research team, were published online in the internationally recognised neuroimaging journal "Brain Research". Utilizing advanced 7T ultra-high-field magnetic resonance imaging technology, the study for the first time introduces a fine depiction of the microscopic structural and functional abnormalities of the attention network in patients with hypertension and cognitive impairment, revealing how blood pressure fluctuations, especially increased pulse pressure, "decelerate" thinking speed by affecting specific brain regions. This study not only provides a brand-new perspective for understanding early cognitive decline related to hypertension, but also lays a scientific foundation for developing more precise early warning and intervention strategies.

Specifically, the study originated from a randomized controlled trial, selecting 41 patients with hypertension and cognitive impairment, and using 7T ultra-high-field magnetic resonance imaging (MRI) to systematically analyze the correlation between global and domain-specific cognitive impairment, neuroimaging indicators, and blood pressure. As found in the study, structural atrophy related to cognitive impairment is localized in brain regions overlapping with the attention network, while functional abnormalities, whether observed at the whole-brain level or within the attention network, were associated with poorer global cognitive performance. Notably, internal functional hyperconnectivity of key hub nodes of the attention network – the right anterior insula and the right posterior intraparietal sulcus – was significantly correlated with decreased processing speed in hypertensive patients and mediated the relationship between pulse pressure and processing speed. These findings provide new insights into the neuropathophysiological mechanisms of hypertension-related cognitive impairment and suggest potential network-based intervention targets.

Reference: Kong, Y., Guo, Q. H., Tang, Y., Xia, S. J., Xu, T. Y., Zhang, J. R.,... & Ma, C. S. (2026). Ultra-high-field 7 T MRI reveals neural abnormalities of attention networks in relation to cognitive impairment in hypertension. Brain Research, 150433.

(2) Multi-domain Digital Cognitive Training for Coronary Heart Disease with Cognitive Impairment ("Heart")

This study is a multi-center randomized controlled trial involving 8 centers in China and including 224 patients, comparing the effects of multi-domain cognitive training provided by the Company with single-domain training in patients with coronary heart disease and mild cognitive impairment. The primary endpoint was the proportion of cognitive function improvement at 12 weeks, and secondary endpoints included quality of life and adherence.

The results showed: ① there was no significant difference in the proportion of cognitive function improvement between the two groups at 12 weeks (p=0.947, OR=1.02, 95% CI 0.51 to 2.05), but both were significantly better than the baseline (p=0.015 and p=0.016); ② adherence in the multi-domain group was significantly better (p=0.009); ③ improvement in quality of life in the multi-domain group was significantly better than the traditional group; ④ the increase in gray matter volume in the left supplementary motor area, right precuneus, and right superior parietal lobule in the multi-domain group was significantly better than the traditional group (Pfamily-wise error=0.004).

Conclusion: the multi-domain cognitive training program demonstrates unique comprehensive advantages in increasing treatment adherence, improving quality of life, and promoting brain plasticity.

These conclusions not only open up a new path for the comprehensive rehabilitation of coronary heart disease, but also demonstrate that cognitive digital therapeutics has gained broad recognition from the international academic community for their value in the cardiovascular field.

Reference: Chen Q, Ye Y, Liu X, et al. Efficacy of computerised cognitive training in patients with coronary heart disease and mild cognitive impairment: a randomised controlled trial. Heart. 2026. DOI: 10.1136/heartjnl-2025-327472.

(3) Research on Dual-Enhancement Training Method for Large Language Models ("Electronics")

The paper "Dual-Enhancement Product Bundling: Bridging Interactive Graph and Large Language Model" by the Group's technical team was published in the international journal "Electronics". Cai Longjun (the CEO of the Group) and Wang Peng (Algorithm Director) are co-corresponding authors, and the recipients of the "Best Researcher Award". This study for the first time proposes a dual-enhancement training framework for large models, combining interactive graph knowledge with the semantic understanding of Large Language Models (LLM) for bundle task recommendation. The proposed Dynamic Concept Binding Mechanism (DCBM) effectively alleviates the cold start problem. This method consistently outperformed all baseline methods across three public datasets, achieving relative improvements of 6.3% – 26.5%, making a valuable contribution to the advancement and research of large language models in the field of reasoning system applications.

III. SIGNIFICANCE OF THE ABOVE ACHIEVEMENTS TO THE GROUP

The championship title secured by the Group, together with the publication of the series of scientific research results, further consolidates the Group's leading advantages in cognitive impairment digital therapeutics and brain science AI:

(1) R&D strength highly recognised by top international academic platforms. Successive publication of results in leading journals such as "Brain Research", "Heart", and "Electronics" marks that the Group's scientific research level has reached the international frontier.

(2) The "Industry-University-Research-Medical" integrated innovation model has achieved significant results. Multiple studies conducted through the Group's deep cooperation with top clinical institutions such as Beijing Anzhen Hospital have validated the feasibility of the "clinical demand – technology R&D – clinical validation" path.

(3) The value of digital therapeutics in the cardiovascular field is supported by high-level evidence-based evidence. Randomized controlled trials confirmed that while maintaining reliable core efficacy, cognitive digital therapeutics can significantly improve adherence and promote brain structural remodeling, providing a new tool for the full-cycle management of cardiovascular diseases.

(4) Application of AI large models in medical vertical fields continues to deepen. The breakthrough in the dual-enhancement method for large language models and the championship title in the competition indicate that the Group is at the forefront of the industry in the integration of large language models and medical scenarios.

The Board believes that the above achievements that align with the Group's long-term development strategy will create long-term value for shareholders.

The contents of this announcement do not constitute connected transactions or notifiable transactions under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Tan Zheng
Chairman and Executive Director

Hong Kong, June 29, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Yang Fan, Ms. Wang Jingbo and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.